India Active Pharmaceutical Ingredients Market, By Manufacturer (Captive AP I and Merchant API), By Synthesis Type (Synthetic and Biotech), By Drug Type (Generic and Branded), By Application (Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other), By Product Type (Low Potent APIs and High Potent APIs), By Formulation (Oral, Topical, Parenteral, Drops, and Others)

Published In : Aug 2024

Code : CMI4785

Pages :325

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Concentration and Competitive Landscape

India Active Pharmaceutical Ingredients Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing investments by global pharmaceutical players

India has emerged as one of the leading locations for active pharmaceutical ingredients (API) production globally. The country accounts for 20% of total global antiretroviral drug production. It is the largest provider of generic medicines worldwide, with the Indian generics accounting for 20% of global exports. Seeing strong growth prospects and affordable skilled labor, many large multi-national pharmaceutical companies have significantly ramped up investments in India over the past few years.

These have set up advanced API manufacturing facilities as well as research & development centers to cater to domestic as well as international markets. Leading players like Dr. Reddy's, Aurobindo Pharma and Sun Pharma are undertaking massive capacity expansion projects. This enables companies to increase scale as well as integration along the pharmaceutical value chain within the country. Growing investments can expand domestic API production capabilities as well as boosts technology upgrades. This attracts even more investments, creating a positive cycle that benefits development of the Indian pharmaceutical industry. Increased investments coupled with cost competitiveness can make India an essential global API supplier.

Key Players Insights